🩺What is Long QT Syndrome?
The QT interval represents the total duration of ventricular depolarization and repolarization on the surface electrocardiogram, measured from the beginning of the QRS complex to the end of the T wave. Because the QT interval varies inversely with heart rate — shortening at faster rates and lengthening at slower rates — a corrected QT interval must be calculated to allow meaningful clinical interpretation independent of rate. The Bazett formula, published in 1920 by Henry Cuthbert Bazett, uses a square root correction: QTc = QT / √RR, where RR is the interval between successive R waves in seconds. The Fridericia formula, published the same year by Louis Sigurd Fridericia, uses a cube root correction: QTc = QT / ∛RR. At heart rates between 60 and 90 beats per minute, both formulas produce similar results. However, at heart rates above 90 bpm, Bazett tends to overcorrect, producing falsely prolonged QTc values, while Fridericia performs more reliably. At heart rates below 60 bpm, both formulas may undercorrect. Other correction formulas exist, including the Framingham linear regression formula, Hodges formula, and individual-specific correction methods, but Bazett remains the most widely used in clinical practice due to its simplicity and historical precedence. The clinical significance of QTc prolongation lies in its association with torsade de pointes, a polymorphic ventricular tachycardia that can degenerate into ventricular fibrillation and cause sudden cardiac death. Both congenital and acquired forms of long QT syndrome are recognized, with over 17 genes implicated in the congenital forms (most commonly KCNQ1, KCNH2, and SCN5A). Acquired QT prolongation is far more common in clinical practice and results from medications (antiarrhythmics, antipsychotics, antibiotics, antihistamines, antidepressants), electrolyte disturbances (hypokalemia, hypomagnesemia, hypocalcemia), bradycardia, myocardial ischemia, intracranial hemorrhage, and hypothyroidism. The incidence of drug-induced torsade de pointes is estimated at 1-10 per 100,000 patient-years, with higher rates in women, older adults, and patients with pre-existing cardiac disease. Gender-specific QTc thresholds are essential because women have inherently longer QTc intervals by approximately 10-20 ms, attributed to the modulating effects of sex hormones on cardiac ion channels, particularly the slower repolarization reserve in women.
📊Clinical Assessment & Risk Scoring
Healthcare professionals use these validated clinical calculators, diagnostic scales, and risk scoring systems to assess the severity, prognosis, or therapeutic dosing requirements for Long QT Syndrome:
QTc Calculator — Corrected QT Interval
The QTc calculator computes the corrected QT interval using both the Bazett and Fridericia formulas, with gender-specific interpretation thresholds for assessing risk of cardiac arrhythmias.
🧬Diagnostic Logic & Scoring Breakdown
The QTc calculator implements two correction formulas to provide a comprehensive rate-corrected QT assessment. The Bazett formula (QTc = QT / √RR) calculates the square root of the RR interval in seconds, where RR = 60 / heart rate in beats per minute. For example, at a heart rate of 60 bpm, RR = 1.0 second and √RR = 1.0, so the correction factor is 1. At a heart rate of 100 bpm, RR = 0.6 seconds and √RR = 0.775, resulting in a larger correction. The Fridericia formula uses the cube root of RR (QTc = QT / ∛RR), which produces a smaller correction factor at elevated heart rates, explaining its greater accuracy in tachycardia. The calculator provides both results simultaneously, allowing the clinician to compare them. If the Bazett QTc is substantially higher than the Fridericia QTc, particularly at heart rates above 90 bpm, the Fridericia value is likely more reliable. Gender-specific interpretation thresholds are applied automatically based on the patient's sex. For adult males, the normal QTc is ≤430 ms (corrected Bazett), borderline is 431-450 ms, and prolonged is >450 ms. For adult females, the normal QTc is ≤450 ms (corrected Bazett), borderline is 451-470 ms, and prolonged is >470 ms. For pediatric patients (1-15 years), normal is ≤440 ms and prolonged is >460 ms regardless of sex. In the presence of wide QRS complex (bundle branch block, ventricular pacing), the QT interval is artifactually prolonged because it includes ventricular activation time. In this situation, the JT interval (JT = QT - QRS) can be used as an alternative, with a corrected JTc of ≤360 ms considered normal. The calculator can also be used to monitor serial QTc changes in patients started on QT-prolonging medications, with a change of >60 ms from baseline or an absolute QTc >500 ms generally considered a threshold for dose adjustment or discontinuation.
📢Clinical Significance & Implications
QTc assessment is a cornerstone of arrhythmia risk stratification in both inpatient and outpatient settings. Clinicians routinely encounter QT-prolonging medications, and awareness of drug-induced QT prolongation is critical for patient safety. Over 100 medications across multiple therapeutic classes are known to prolong the QT interval, including class IA and III antiarrhythmics (quinidine, sotalol, amiodarone, dofetilide), macrolide antibiotics (azithromycin, erythromycin), fluoroquinolones (levofloxacin, moxifloxacin), antipsychotics (haloperidol, ziprasidone, quetiapine), antidepressants (citalopram, escitalopram), antiemetics (ondansetron, domperidone), antimalarials (chloroquine, hydroxychloroquine), opiate agonists (methadone), and antifungal agents. The risk of drug-induced torsade de pointes increases when multiple QT-prolonging drugs are combined, when drugs are given in high doses or by rapid intravenous infusion, or when concomitant electrolyte disturbances exist. Hypokalemia is the most common electrolyte abnormality predisposing to QT prolongation, as low extracellular potassium reduces the repolarization reserve by decreasing the rapid component of the delayed rectifier potassium current (IKr). Hypomagnesemia potentiates the proarrhythmic effects of hypokalemia, making the synergistic effects of diuretic therapy particularly dangerous. The QTc interval is also used in the diagnosis and monitoring of congenital long QT syndrome (LQTS). Genetic testing is recommended for patients with QTc >500 ms after excluding acquired causes, those with a Schwartz score ≥3.5, and family members of known LQTS probands. LQTS genotype-phenotype correlations are well-established: LQT1 (KCNQ1 mutation) typically presents with exercise-induced events, LQT2 (KCNH2 mutation) is triggered by auditory stimuli or emotional stress, and LQT3 (SCN5A mutation) occurs during sleep or rest. The European Medicines Agency and FDA recommend ECG monitoring for all drugs with known QT-prolonging potential during clinical development, and regulatory decisions have been influenced by QT prolongation signals. In addition, QTc prolongation is an independent predictor of mortality in the general population, with a meta-analysis of over 100,000 individuals showing a hazard ratio of 1.3 for cardiovascular mortality for each 50 ms increase in QTc beyond the normal range.
💡 Clinical Assessment Scenario Example
A 45-year-old woman with no prior cardiac history presents to the emergency department with palpitations and lightheadedness. Her vital signs are stable except for a heart rate of 100 bpm. The initial ECG shows sinus tachycardia with a QT interval of 360 ms. She has been started on citalopram 40 mg daily by her primary care physician three weeks ago for depression. Her laboratory studies show: potassium 3.3 mEq/L (mild hypokalemia), magnesium 1.9 mg/dL, calcium 9.0 mg/dL, and normal renal function. She is not on any diuretics, but reports increased intake of caffeinated beverages and reduced appetite since starting the antidepressant. Calculation: HR = 100 bpm → RR = 60/100 = 0.6 seconds. Bazett QTc = 360 / √0.6 = 360 / 0.775 = 465 ms. Fridericia QTc = 360 / ∛0.6 = 360 / 0.843 = 427 ms. Interpretation: Using the Bazett formula, her QTc of 465 ms falls in the borderline-prolonged range (normal for females ≤450 ms). However, given her tachycardia, the Fridericia formula produces a QTc of 427 ms, which is within normal limits. The discrepancy between the two formulas at a heart rate of 100 bpm illustrates the known overcorrection of the Bazett formula in tachycardia. Despite this, clinical concern remains due to the combination of moderate-dose citalopram (a known QT-prolonging antidepressant), mild hypokalemia, and a borderline Bazett QTc. Management: The patient is given oral potassium chloride 40 mEq and oral magnesium oxide 400 mg. She receives a bolus of normal saline. Citalopram is held, and her primary care physician is contacted for alternative antidepressant options. Repeat ECG after electrolyte correction shows a heart rate of 82 bpm, QT of 400 ms, RR of 0.73 seconds, Bazett QTc of 400/√0.73 = 400/0.854 = 468 ms, Fridericia QTc of 400/∛0.73 = 400/0.90 = 444 ms. The persistently prolonged Bazett QTc with a normal Fridericia QTc supports overcorrection artifact, but given the ongoing QT-prolonging medication effect and contributing hypokalemia, the patient is counseled on risk factors for QT prolongation and instructed to avoid additional QT-prolonging agents.
💊Common Medications & Interventions
The following pharmacological therapies and substances are commonly referenced or adjusted based on the clinical assessment of Long QT Syndrome:
⚠️Clinical Assessment Pitfalls
❌ Mistake: Using the Bazett formula exclusively at high heart rates
✅ Correction: Bazett overcorrects at HR >90 bpm, producing falsely prolonged QTc values. Always check the Fridericia-corrected QTc in tachycardic patients, as it is more reliable at elevated heart rates. A discrepancy between Bazett and Fridericia >30 ms should prompt reliance on the Fridericia value.
❌ Mistake: Including U waves in the QT measurement
✅ Correction: The QT interval should be measured from the onset of the QRS complex to the end of the T wave, defined as the point where the T wave returns to the isoelectric baseline. U waves are not part of the T wave and must not be included. When T and U waves are fused, use the descending limb tangent method to identify the end of T.
❌ Mistake: Applying the same QTc thresholds regardless of gender
✅ Correction: Gender-specific thresholds are essential: normal QTc in males is ≤430 ms, while in females it is ≤450 ms. Using male thresholds for female patients would underestimate risk, and vice versa would cause unnecessary concern.
❌ Mistake: Ignoring the impact of QRS duration on QT interpretation
✅ Correction: In patients with wide QRS (BBB, ventricular pacing, WPW), the QT interval is artifactually prolonged. Use the JT interval (QT - QRS) or corrected JTc (JTc = JT/√RR). A JTc >360 ms or QRS-adjusted QTc can provide a more accurate assessment of repolarization.
❌ Mistake: Not adjusting medication doses or monitoring ECG when initiating QT-prolonging drugs
✅ Correction: Baseline and follow-up ECG monitoring is recommended when initiating or uptitrating QT-prolonging medications, particularly in patients with pre-existing risk factors (female sex, age >65, electrolyte abnormalities, bradycardia, renal/hepatic impairment, concurrent QT-prolonging drugs). A QTc increase >60 ms from baseline or QTc >500 ms warrants dose reduction or alternative therapy.
🚑When to Seek Medical Attention
This reference supports clinical assessment of Long QT Syndrome; it does not replace urgent evaluation. Seek prompt in-person medical care if symptoms are severe, rapidly worsening, or life-threatening, or if you are unsure about a diagnosis or treatment plan. Patients should always consult their physician before starting or changing any therapy.
❓Frequently Asked Questions
Q: Which QTc formula is more accurate?
Bazett is the most commonly used formula due to its simplicity but tends to overcorrect at heart rates >90 bpm, producing falsely prolonged QTc. Fridericia is more accurate at elevated heart rates and is recommended by some electrophysiology societies. For heart rates between 60-90 bpm, both formulas produce similar results. The Framingham linear formula and the Hodges formula are alternatives that perform better across a wider range of heart rates but are less commonly used in clinical practice.
Q: What are the most common causes of acquired QT prolongation?
Medications are the most common cause, including class IA and III antiarrhythmics (sotalol, amiodarone, dofetilide, quinidine), antipsychotics (haloperidol, ziprasidone), antidepressants (citalopram, escitalopram), antibiotics (azithromycin, erythromycin, levofloxacin, moxifloxacin), antiemetics (ondansetron, domperidone), opiate agonists (methadone), and antimalarials. Electrolyte disturbances (hypokalemia, hypomagnesemia, hypocalcemia), bradycardia, myocardial ischemia, intracranial hemorrhage, hypothyroidism, anorexia nervosa, and severe illness are also important causes.
Q: When should I consider genetic testing for Long QT Syndrome?
Genetic testing is recommended for: (1) patients with QTc >500 ms after excluding acquired causes (medications, electrolytes); (2) patients with a Schwartz score ≥3.5; (3) asymptomatic patients with QTc >470 ms (males) or >480 ms (females) if congenital LQTS is suspected; (4) first-degree relatives of a known LQTS proband; (5) patients with unexplained cardiac arrest or documented torsade de pointes without an identifiable cause.
Q: Can hypokalemia alone cause torsade de pointes?
Yes, hypokalemia alone can prolong the QT interval and precipitate torsade de pointes, particularly when potassium falls below 2.5 mEq/L. Hypokalemia reduces IKr potassium current and slows repolarization, creating a substrate for early afterdepolarizations. Hypomagnesemia potentiates this effect. The risk is amplified when hypokalemia is combined with QT-prolonging medications, a common scenario in patients receiving diuretic therapy.
Q: What is the Schwartz score for LQTS diagnosis?
The Schwartz score (1993, updated 2006) is a clinical diagnostic scoring system for congenital Long QT Syndrome. Points are assigned for: ECG findings (QTc ≥480 ms = 3 pts; 460-479 = 2 pts; 450-459 males = 1 pt; torsade de pointes = 2 pts; T wave alternans = 1 pt; notched T wave in 3 leads = 1 pt), clinical history (syncope with stress = 2 pts, without stress = 1 pt; congenital deafness = 0.5 pt), and family history (definite LQTS = 1 pt; unexplained sudden death <30 y in first-degree = 0.5 pt). Score: ≤1 = low probability, 1.5-3 = intermediate probability, ≥3.5 = high probability.
Q: How should I monitor a patient on a QT-prolonging medication?
Obtain a baseline ECG before starting the medication. Repeat ECG at steady state (5 half-lives or 2 weeks into therapy), after dose increases, and when adding any additional QT-prolonging agent. Discontinue or reduce dose if QTc increases >60 ms from baseline or exceeds 500 ms. Correct any electrolyte abnormalities. Consider alternative medication if QTc remains borderline prolonged.
Q: Is LVEF assessment needed in QTc prolongation evaluation?
Yes. QTc prolongation is associated with cardiomyopathy, and structural heart disease increases the risk of torsade de pointes. Echocardiography is recommended to assess LVEF in patients with unexplained QTc prolongation. Additionally, acute QTc prolongation can occur during Takotsubo cardiomyopathy, acute myocardial ischemia, or subarachnoid hemorrhage, and the QTc typically normalizes with recovery of the underlying condition.